RAPP
HealthcareRapport Therapeutics, Inc. Common Stock
Key Drivers
- Strong liquidity
- Ongoing losses
- Negative cash flow
AIAI Summary
RAPP has moved from a speculative biotech to a credible late-stage opportunity as RAP-219 now shows durable seizure reduction and a long half-life, but the investment case remains binary on Phase 3 execution because the stock has already rerated and any clinical miss could quickly erase upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Ongoing losses
- •Negative cash flow
RAPP has excellent liquidity and minimal leverage, but persistent losses, negative cash flow, and weak operating efficiency make its fundamentals difficult to justify.
Price Behavior
Key Price Behavior Insights:
- •Support bounce
- •Resistance cap
- •Momentum fade
Over the last month, RAPP has been mixed to slightly negative, bouncing sharply from low-$33 support to near $40 before fading back into the mid-$37s as $38.4-$39.9 resistance caps upside.
Sharp rebound from low-$33 support to $39.93, then momentum faded
Sentiment & News
Key News Insights:
- •Seizure durability
- •Phase 3 timing
- •China expansion
Rapport Therapeutics' latest updates were broadly positive, highlighted by sustained RAP-219 seizure reduction, a narrow Q1 loss beat, an on-track Phase 3 start, an earlier bipolar mania readout, and a China partnership, despite notable insider selling.
The news flow is modestly bullish for the stock, with strong clinical momentum and a long cash runway outweighing the insider-selling overhang
Similar Companies in Healthcare
Other companies in the same sector with AI ratings